Stifel analyst David Grossman raised the firm’s price target on Accenture to $375 from $340 and keeps a Buy rating on the shares after the company reported in-line Q4 results. The firm noted that Q1 and FY25 guidance were “largely in-line” with Wall Street estimates, and that underlying fundamentals appear to be stabilizing. Stifel added that its positive longer-term thesis remains unchanged, though the stock is likely range-bound pending cyclical recovery in shorter-term consulting bookings. Sequential headcount growth adds a positive to the story, with bookings more heavily indexed to larger/slower conversion deals, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACN:
- Accenture upgraded to Overweight at Piper on ‘attractive’ FY25 set-up
- Accenture upgraded to Outperform from Neutral at Piper Sandler
- Micron reports Q4 beat, Pfizer withdraws Oxbryta: Morning Buzz
- Unusually active option classes on open September 26th
- Morning Movers: Micron and Accenture rise following quarterly results